Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + hyper-CVAD
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Everolimus + hyper-CVAD is a combination therapy investigated for the treatment of relapsed or refractory acute lymphocytic leukemia (ALL). Everolimus (RAD001) is an oral small molecule inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that plays a critical role in regulating cell growth, proliferation, and survival. Hyper-CVAD is a dose-intensive chemotherapy regimen consisting of two alternating cycles: Part A (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and Part B (methotrexate and cytarabine). The rationale for adding everolimus to this standard chemotherapy backbone is to inhibit the PI3K/Akt/mTOR pathway, which is frequently activated in ALL and contributes to chemoresistance. This specific combination has been evaluated in Phase I/II clinical trials led by the M.D. Anderson Cancer Center to determine if mTOR inhibition can improve clinical outcomes in difficult-to-treat ALL cases.
- Brand names
- AfinitorZortress
- Other names
- RAD001 + hyper-CVADeverolimus + cyclophosphamide + vincristine + doxorubicin + dexamethasone + methotrexate + cytarabine
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA polymerase familyMechanistic target of rapamycin complex 1GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on everolimus + hyper-CVAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + hyper-CVAD.